Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.23.00252 JCO Precision Oncology no. 7 (2023) e2300252. Published online December 1, 2023. PMID: 38039431 Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer Deepak Bhamidipati , MD1xDeepak BhamidipatiSearch for articles by this author; Sireesha Yedururi , MD2xSireesha YedururiSearch for articles by this author; Jason Huse, MD3xJason HuseSearch for articles by this author; Sri Veda Chinapuvvula4xSri Veda ChinapuvvulaSearch for articles by this author; Jie Wu , PhD5xJie WuSearch for articles by this author; and Vivek Subbiah , MD6,7,8,9xVivek SubbiahSearch for articles by this author Show More 1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX2Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX3Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX4Medical Science Academy, Hightower High School, Houston, TX5Peggy and Charles Stephenson Cancer Center and the Department of Pathology, The University of Oklahoma Health Science Center, Oklahoma City, OK6Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX7Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX8MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, TX9Sarah Cannon Research Institute, Nashville, TN https://doi.org/10.1200/PO.23.00252 First Page Full Text PDF Figures and Tables Supplements © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsFinancial support: Jie Wu, Jie WuAdministrative support: Vivek Subbiah, Vivek SubbiahProvision of study materials or patients: Sireesha Yedururi, Vivek Subbiah, Sireesha Yedururi, Vivek SubbiahCollection and assembly of data: Vivek Subbiah, Vivek SubbiahData analysis and interpretation: Deepak Bhamidipati, Jason Huse, Sri Veda Chinapuvvula, Jie Wu, Deepak Bhamidipati, Jason Huse, Sri Veda Chinapuvvula, Jie WuManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Jason HuseResearch Funding: Taiho Pharmaceutical (Inst)Travel, Accommodations, Expenses: Taiho PharmaceuticalVivek SubbiahConsulting or Advisory Role: MedImmune, Helsinn Therapeutics, Relay Therapeutics, Pfizer, Loxo/LillyResearch Funding: Novartis (Inst), GlaxoSmithKline (Inst), NanoCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech/Roche (Inst), Berg Pharma (Inst), Bayer (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), Amgen (Inst), AbbVie (Inst), Multivir (Inst), Blueprint Medicines (Inst), LOXO (Inst), Vegenics (Inst), Takeda (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Biomedical (Inst), Inhibrx (Inst), Exelixis (Inst), Amgen (Inst), Turning Point Therapeutics (Inst), Relay Therapeutics (Inst)Travel, Accommodations, Expenses: PharmaMar, Bayer, Novartis, Helsinn Therapeutics, Foundation MedicineOther Relationship: MedscapeNo other potential conflicts of interest were reported.